Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed a Letter of Intent (“LOI”) with Pharmaflorx Ltd. (“PFX”) for the supply of cannabis oils and isolates. PFX is a privately-held late-stage Access to Cannabis for Medical Purposes Regulations (“ACMPR”) applicant located in Gatineau, Quebec. Per the update, Pivot will acquire a minimum of 1,000 kg/year of cannabis oils or isolates from PFX to manufacture its patented portfolio of biocannabis products. Pivot intends to supply both the Canadian and European Union markets with its suite of patented products following receipt of fitting licenses where regulations permit. “We welcome Pharmaflorx to our growing list of strategic partners and look forward to collaborating with their team to provide a steady and consistent supply of premium cannabis oils and isolates for Pivot’s portfolio of products,” Pivot CEO Dr. Patrick Frankham stated in the news release. “We continue to execute aggressively on our business plan to bring Pivot’s industry leading pipeline of derivatives to market by the end of this year.”
To view the full press release, visit http://cnw.fm/4RyLh
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to Ready-To-Infuse Cannabis (“RTIC”) oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based products. For more information, visit the company’s website at www.PivotPharma.com.
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com